Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

Abstract Background Early-stage breast cancer (BC) diagnosis significantly reduces mortality, yet relapse remains a concern due to undetectable minimal residual disease (MRD). Liquid biopsies offer real-time insights into tumor dynamics, aiding MRD detection and therapy response evaluation. However,...

詳細記述

書誌詳細

主要な著者:	Iñaki Comino-Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, Maria Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Angel Guerrero-Zotano
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-05-01
シリーズ:	Breast Cancer Research
主題:	Liquid biopsy Early breast cancer Circulating tumor DNA Minimal residual disease
オンライン･アクセス:	https://doi.org/10.1186/s13058-025-02016-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!